Share
Services
The healthcare group Fresenius strengthens its Management Board team. The Supervisory Board of Fresenius Management SE has appointed Pierluigi Antonelli (56) as Chief Executive Officer of Fresenius Kabi with effect from 1 March 2023. He succeeds Michael Sen, who had held this position on an interim basis after being appointed Chairman of the Management Board of Fresenius on 1 October 2022. The current scope of the Human Resources, Risk Management and Legal departments will be broadened to also cover Environmental, Social and Governance (ESG) going forward. Sebastian Biedenkopf (58) will leave the company by mutual agreement once his contract expires at the end of the year. He will support his successor Michael Moser (46), who will join Fresenius on 1 August 2023 at the latest, until the end of his contract to ensure a seamless handover.
“With Pierluigi Antonelli and Michael Moser, two internationally experienced top managers are joining our company. I am very pleased that they are joining the team and taking over responsibility as we are shaping #FutureFresenius in the coming years,” said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius. “I would like to thank Sebastian Biedenkopf for his great commitment over the past years. In his role, he has made strong contributions to maintain Fresenius’ stability during challenging times. We wish him all the best in his future endeavours, both professionally and personally.”
Pierluigi Antonelli joins Fresenius with extensive operational expertise in the pharmaceutical industry with a focus on product development and launches across key international markets, business development and strategy crafting as well as implementation. In his previous role since 2019, he was the CEO of Angelini Pharma, a subsidiary of the Italian Angelini Group specializing in brain health and consumer health. Prior to that, he held senior leadership positions at Novartis Oncology, Sandoz, Merck & Co. and Bristol Myers Squibb in the United States and across Europe, and beyond.
Michael Moser served as deputy CEO and CFO at Enerjisa, the leading energy company in Turkey, since 2019. Previously, since 2008, he held various leadership positions at energy provider E.ON, one of the major investors in Energjisa. During his time at E.ON, Moser was, among other things, a board member with responsibility for legal, compliance, M&A and portfolio optimization at the listed company Eneva in Brazil and later also responsible for the spin-off and IPO of the German energy company Uniper. With a degree in law and business administration, he started his career at Baker & McKenzie with a focus on M&A and corporate law. In recent years, he has worked in various countries including the United States, China, Brazil, France, the United Kingdom and Switzerland.
“The trajectory of Fresenius Kabi has been set with ‘Vision 2026’ towards profitable growth,” said Fresenius CEO Michael Sen. “Thanks to his many years of experience in the pharmaceutical sector, Pierluigi Antonelli has the expertise to further support Fresenius Kabi on this journey. Michael Moser is not only a proven expert in the areas of compliance and risk management, but also brings extensive experience in portfolio management and navigating periods of transformation as well as in the energy industry managing sustainability issues.”
“I would like to thank the Supervisory Board of Fresenius Management SE for the trust they have placed in me,” said Pierluigi Antonelli. “Fresenius Kabi operates at the heart of Fresenius with a clear direction laid out with ‘Vision 2026’, which we will further shape together. I can hardly imagine a more exciting opportunity than leading this company into the future. Fresenius Kabi is already a market leader across multiple markets, offering healthcare products and solutions for chronically ill patients and competing in dynamic growth areas with biosimilars and MedTech. I will focus on working with the team to further strengthen the company's position and drive profitable growth across the focus segments.”
“Fresenius is a great company, which, with its employees around the world, will decisively shape the future of medical technology and health,” said Michael Moser. “What always fascinates and motivates me, across all my professional activities, is people. Fresenius cares about people's health in a special way. I am very much looking forward to contributing to Fresenius’ journey with my experience in change and growth processes, and in working together with the entire workforce to drive transformation processes.”
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
The Fresenius Group expresses its deepest sympathies and condolences to the families and individuals affected by the earthquakes in Türkiye and Syria.
As first reaction after the catastrophic event, the company fully focused on connecting with its patients in the region. People dependent on our lifesaving products and services were transferred in case of destruction of local infrastructure. As further immediate step, Fresenius Medical Care established contact with its employees on site and intensively looks into options to support its local staff and their families.
Our disaster response teams are in full action and are being supported by units from other parts of the country. As global healthcare company, Fresenius is committed to support with urgently needed medical supply and works with humanitarian aid organizations to deliver donations of its most critical care products and services.
We remain fully committed to our patients, local staff, and partners on site.
Michael Sen, CEO of Fresenius
In this year's ranking, CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 680 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.
In this year's ranking, CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 680 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.
Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent of companies based on S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Occupational Health and Safety, Climate Strategy, as well as Risk and Crisis Management.
Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent of companies based on S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Occupational Health and Safety, Climate Strategy, as well as Risk and Crisis Management.
Dennis Hofmann has been appointed Head of Global Corporate Communications at Fresenius. He succeeds the previous Head of Communications Matthias Link, who will leave the company after 14 years by mutual agreement end of 2022. In his new role, Dennis Hofmann will report to the CEO, Michael Sen and work closely with him, the Management Board and senior executives on all aspects of strategic communications. Dennis will also be responsible for coordinating relevant strategic comms activities within the Fresenius Group and across different business segments.
“I would like to express my sincere gratitude to Matthias Link for his many years of very successful commitment and service to our company and wish him all the best for his future endeavors. Equally, I am very much looking forward to working with Dennis Hofmann. In Dennis, we gain a proven communications expert with a good understanding of people and issues relevant to the company. His diverse communications experience across industries and surrounding the implementation of transformation processes will further strengthen Fresenius’ positioning as a leading healthcare company and make him an asset to our management team”, said Michael Sen, CEO of Fresenius.
“Now more than ever, communication plays a crucial role on the path to #FutureFresenius. I am honored to lead the communications department of such a great company”, Hofmann said. “Every day, more than 300,000 employees worldwide contribute to improving the quality of life of millions of people. It's a privilege to be part of Fresenius’ mission and I will work with my team to ensure we deliver strong corporate communications support that drives business growth and cultural change.”
Dennis Hofmann took up his position as Head of Global Communications at Fresenius Kabi in September 2022. Previously, he spent several years in senior positions within the communications, marketing, and investor relations fields. Most recently he served as Senior Vice President for Corporate Communications & Investor Relations at Leoni AG in Nuremberg. Prior to that, he spent approximately 18 years at Siemens AG where, in his final four years, he held the position of Corporate Senior Vice President for Global Internal and External Communications.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.
Fresenius today successfully placed bonds with an aggregate volume of €1 billion across two tranches:
The proceeds will be used for general corporate purposes, including refinancing of existing financial liabilities.
The bonds were drawn under the Fresenius Debt Issuance Program (DIP) and issued by Fresenius SE & Co KGaA. Fresenius has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.
The envisaged settlement date is November 28, 2022.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This announcement is a general information and not a prospectus. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus to be issued by the company in connection with the offering of such securities. Copies of the prospectus will, following publication, be available free of charge from Fresenius SE & Co. KGaA at Else-Kröner Strasse 1, 61352 Bad Homburg, Germany.
This announcement has been prepared on the basis that any offer of securities in any Member State of the European Economic Area ("EEA") will be made pursuant to the prospectus prepared by Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company in combination with the relevant final terms relating to such securities or pursuant to an exemption under Regulation (EU) 1129/2017 (the Prospectus Regulation) from the requirement to publish a prospectus for offers of securities. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company have authorized, nor do they authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company or any other person to publish or supplement a prospectus for such offer.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
With regard to the EEA and the United Kingdom ("UK"), the identified target market for the securities referred to in this press release is eligible counterparties and professional clients only. No key information document (KID) within the meaning of Regulation (EU) No 1286/2014 (as amended the "PRIIPs Regulation") or the PRIIPS Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 (EUWA) (the "UK PRIIPs Regulation"), as applicable, has been prepared and therefore offering or selling the securities or otherwise making them available to any retail investor in the EEA or UK will be unlawful under the PRIIPs Regulation or UK PRIIPS Regulation, as applicable.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company undertake any responsibility to update the forward-looking statements in this announcement.
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.
Fresenius today successfully placed bonds with an aggregate volume of €1 billion across two tranches:
The proceeds will be used for general corporate purposes, including refinancing of existing financial liabilities.
The bonds were drawn under the Fresenius Debt Issuance Program (DIP) and issued by Fresenius SE & Co KGaA. Fresenius has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.
The envisaged settlement date is November 28, 2022.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This announcement is a general information and not a prospectus. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus to be issued by the company in connection with the offering of such securities. Copies of the prospectus will, following publication, be available free of charge from Fresenius SE & Co. KGaA at Else-Kröner Strasse 1, 61352 Bad Homburg, Germany.
This announcement has been prepared on the basis that any offer of securities in any Member State of the European Economic Area (EEA) will be made pursuant to the prospectus prepared by Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company in combination with the relevant final terms relating to such securities or pursuant to an exemption under Regulation (EU) 1129/2017 (the Prospectus Regulation) from the requirement to publish a prospectus for offers of securities. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company have authorized, nor do they authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company or any other person to publish or supplement a prospectus for such offer.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
With regard to the European Economic Area ("EEA") and the United Kingdom ("UK"), the identified target market for the securities referred to in this press release is eligible counterparties and professional clients only. No key information document (KID) within the meaning of Regulation (EU) No 1286/2014 (as amended the "PRIIPs Regulation") or the PRIIPS Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 (EUWA) (the "UK PRIIPs Regulation"), as applicable, has been prepared and therefore offering or selling the securities or otherwise making them available to any retail investor in the EEA or UK will be unlawful under the PRIIPs Regulation or UK PRIIPS Regulation, as applicable.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company undertake any responsibility to update the forward-looking statements in this announcement.
